Roche Partners with Customers, Redefines Laboratory Value

The AACC 2014 Clinical Lab Expo two-booth approach allows customers to see how Roche is partnering with them today and tomorrow. Roche (Basel, Switzerland) launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo by unveiling two booths focused on the distinctive ways Roche is partnering with customers to redefine the value of the laboratory.

In one booth Roche is exhibiting a variety of in vitro diagnostics solutions designed to enhance testing efficiency and provide reliable clinical information from central labs to hospital point of care (POC), clinics, and patient homes. Specific product areas include integrated clinical chemistry and immunoassay analyzers, molecular diagnostics platforms, lab automation, immunohistochemistry/in situ hybridization systems, handheld point-of-care (POC) testing monitors, and information technology solutions.

In the second booth, the Roche SmartLab Theatre, attendees can hear directly from clinical and industry experts about important updates in automation, change management, personalized healthcare and other key topics. Roche is unveiling a unique self-guided gallery walk with interactive kiosks, where attendees can explore the company's investments in the three areas: IT solutions, peer connectivity, and support and education. In this booth, attendees can learn how Roche is transforming information into intelligence.

An overview of both booths, as well as a schedule of SmartLab Theatre presentations and times and locations of Roche-sponsored events, can be found online (please see Related Links below),

Roche is also discussing critical industry issues by sponsoring four workshops: building collaborative partnerships for the future of the lab, a new process to achieve chest pain accreditation, hemoglobin A1c, assuring confidence and efficiency in clinical practice, and NT-proBNP: analytical and clinical considerations for improving patient care.

New products featured by Roche this year include: cobas u 601 urine analyzer: a new, fully automated solution for urine strip testing in mid-to high-volume labs that delivers high-quality results through reagent test strips proven in 50 years of urinalysis testing.

cobas 8100 automated workflow series is new modular solution delivers automation without compromise by providing multilevel, bidirectional sample transport; workflow your way; and hands-free add-on/repeat testing. It is designed to eliminate technical barriers that spoil true hands-off testing.

cobas CT/NG v2.0 tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in symptomatic and asymptomatic patients. It is cleared for use with male/female urine, self-collected and clinician-collected vaginal, and endocervical swab specimens, all collected in cobas PCR media, and cervical specimens collected in PreservCyt solution.

cobas HPV is an automated, DNA-based test approved by the US FDA for first-line primary screening for cervical cancer. Approved for use with women 25 and older, it provides 3 results in 1 test: individual results for HPV 16 and 18 genotypes and a pooled result for the 12 other high-risk types, all in one run, from one patient sample.

Elecsys Calcitonin immunoassay gives the in vitro quantitative determination of human calcitonin in serum and plasma.

Elecsys CMV immunoglobulin G (IgG) assay could be used as an aid in determining the serological status to the Cytomegalovirus (CMV) in individuals in which a CMV IgG test was ordered, including pregnant women.

Elecsys HBeAg immunoassay is an immunoassay for the in vitro quantitative determination of Hepatitis B e antigen in human serum or plasma (K2-EDTA, lithium or sodium heparin, and sodium citrate) in adult patients with symptoms of Hepatitis or at risk for Hepatitis B virus (HBV) infection.

Related Links:
Roche
Roche at AACC 2014